DOI QR코드

DOI QR Code

Pemetrexed is Mildly Active with Good Tolerability for Treatment of Patients with Colorectal Cancer

  • Zhang, Hui-Qing (Department of General Surgery, Heping Hospital of Changzhi Medical College) ;
  • Lian, Chang-Hong (Department of General Surgery, Heping Hospital of Changzhi Medical College) ;
  • Ping, Yao-Dong (Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)) ;
  • Song, Wen-Bin (Department of General Surgery, Heping Hospital of Changzhi Medical College) ;
  • Lu, Qing-Pu (Department of Pharmacy, Peking University Cancer Hospital & Institute) ;
  • Xie, Shu-Zhe (Department of Pharmacy, Peking University Cancer Hospital & Institute) ;
  • Lin, Tao (Department of Pharmacy, Peking University Cancer Hospital & Institute) ;
  • Cheng, Lin-Zhong (Department of Pharmacy, Heping Hospital of Changzhi Medical College)
  • Published : 2014.10.23

Abstract

Purpose: This systematic analysis was conducted to evaluate the efficacy and safety of pemetrexed based salvage chemotherapy for treatment of patients with metastatic colorectal cancer. Methods: Clinical studies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for patients with colorectal cancer were identified using a predefined search strategy. Pooled response rates (RRs) were calculated. Results: For pemetrexed based regimens, 4 clinical studies including 201 patients with advanced colorectal cancer were considered eligible for inclusion. The analysis suggested that, in all patients, pooled RR was 20.4% (41/201). Major adverse effects were neutropenia, anorexia, fatigue, and anemia. No treatment related death occurred with pemetrexed based treatment. Conclusion: This systematic analysis suggests that pemetrexed based regimens are associated with mild activity with good tolerability in treating patients with metastatic colorectal cancer.

Keywords

Metastatic colorectal cancer;pemetrexed chemotherapy;response rate

References

  1. Cripps C, Burnell M, Jolivet J, et al (1999). Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol, 10, 1175-9. https://doi.org/10.1023/A:1008372529239
  2. Abad A, Navarro M, Sastre J, et al (1997). A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group). Oncology, 11, 53-7.
  3. Adjani AA (2003). Pemetrexed (ALIMTAw): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther, 3, 145-55. https://doi.org/10.1586/14737140.3.2.145
  4. Adjei A (2004). Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res, 10, s4276-80. https://doi.org/10.1158/1078-0432.CCR-040010
  5. Atkins JN, Jacobs SA, Wieand HS, et al (2005). Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. Clin Colorectal Cancer, 5, 181-7. https://doi.org/10.3816/CCC.2005.n.029
  6. Chen Q, Xia HW, Ge XJ, et al (2013). Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev, 14, 7421-6. https://doi.org/10.7314/APJCP.2013.14.12.7421
  7. Grem JL. Fluorinated pyrimidines (1990). In Chabner BA, Collins JM (eds): Cancer Chemotherapy: Principles and Practice. Philadelphia, PA: Lippincott, 180-24.
  8. Grindey GB, Shih C, Barnett CJ et al (1992). LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res, 33, 411 (Abstr).
  9. Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001). Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist, 6, 363-73. https://doi.org/10.1634/theoncologist.6-4-363
  10. Hazarika M, White RM, Johnson JR, et al (2004). FDA drug approval summaries: pemetrexed (Alimta$^{(R)}$). Oncologist, 9, 482-8. https://doi.org/10.1634/theoncologist.9-5-482
  11. Hochster H, Kettner E, Kroning H, et al (2005). Phase I/II doseescalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. Clin Colorectal Cancer, 5, 257-62. https://doi.org/10.3816/CCC.2005.n.036
  12. Louvet C1, Andre T, Gamelin E, et al (2010). Phase II study of biweekly pemetrexed plus irinotecan as second-line therapy for metastatic colorectal cancer. J Oncol, 2010, 785934.
  13. Hu XQ, Yuan P, Luan RS, et al (2013). Calpain-10 SNP43 and SNP19 polymorphisms and colorectal cancer: a matched case-control study. Asian Pac J Cancer Prev, 14, 6673-80 https://doi.org/10.7314/APJCP.2013.14.11.6673
  14. John W, Picus J, Blanke CD, et al (2000). Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer, 8, 1807-13.
  15. Louvet C (2004), Pemetrexed in advanced colorectal cancer. Oncology, 18, 56-62.
  16. Mendelsohn LG, Shih C, Chen VJ et al (1999). Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol, 26, 42-7.
  17. Niyikiza C, Baker SD, Seitz DE, et al (2002). Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther, 1, 545-552.
  18. Pandurangan AK, Ananda Sadagopan SK, Dharmalingam P, et al (2013). Luteolin, a bioflavonoid, attenuates azoxymethaneinduced effects on mitochondrial enzymes in BALB/c mice. Asian Pac J Cancer Prev, 14, 6669-72. https://doi.org/10.7314/APJCP.2013.14.11.6669
  19. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43 https://doi.org/10.1016/S1470-2045(01)00486-7
  20. Renaldo DA, Burris HA, Dorr FA et al (1995). Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol, 13, 2842-50.
  21. Ronald DA, Kuhn JG, Burris HA et al (1999). A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol, 44, 372-80. https://doi.org/10.1007/s002800050992
  22. Shih C, Grindey GB, Barnett CJ et al (1992). Structure-activity relationship studies of novel pyrrolopyrimidine antifolate LY231514. Proc Am Assoc Cancer Res, 33, 411 (Abstr).
  23. Rowinsky EK, Beeram M, Hammond LA, et al (2007). A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. Clin Cancer Res, 13, 532-9. https://doi.org/10.1158/1078-0432.CCR-06-1606
  24. Schilsky RL (1992). Antimetabolites. In Perry MC (ed.): The Chemotherapy Source Book. Baltimore, MD: Williams and Wilkins, 301-15.
  25. Shih C, Chen VC, Gossett LS et al (1997). LY231514, a pyrrolo (2, 3-d) pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res, 57, 1116-23.
  26. Shih C, Thornton DE (1999). Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514).
  27. In Jackman AL (ed.): Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy. Totowa, NJ: Humana Press, Inc, 183-01.
  28. Simsek EN, Uysal T (2013). In vitro investigation of cytotoxic and apoptotic effects of Cynara L. species in colorectal cancer cells. Asian Pac J Cancer Prev, 14, 6791-5. https://doi.org/10.7314/APJCP.2013.14.11.6791
  29. Sung JJ, Lau JY, Goh KL, et a1 (2005). Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncel, 6, 871-6. https://doi.org/10.1016/S1470-2045(05)70422-8
  30. Underhill C1, Goldstein D, Gorbounova VA, et al (2007). A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. Oncology, 73, 9-20. https://doi.org/10.1159/000120626
  31. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar$^{(R)}$ combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  32. Yu M, Niu ZM, Wei YQ (2013). Effective response of the peritoneum microenvironment to peritoneal and systemic metastasis from colorectal carcinoma. Asian Pac J Cancer Prev, 14, 7289-94. https://doi.org/10.7314/APJCP.2013.14.12.7289

Cited by

  1. Types of Cancers Prevailing in Pakistan and their Management Evaluation vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3605